Tags

Type your tag names separated by a space and hit enter

Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It?
J Leg Med. 2019 Apr-Jun; 39(2):137-149.JL

Links

Publisher Full Text

Authors

Hyman DA
No affiliation info available
Silver C
No affiliation info available

MeSH

CommerceCost ControlDrug IndustryDrug and Narcotic ControlEconomic CompetitionEthics, BusinessGovernment RegulationHumansPharmaceutical PreparationsUnited StatesUnited States Food and Drug Administration

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31503533

Citation

Hyman, David A., and Charles Silver. "Why Are We Being Overcharged for Pharmaceuticals? what Should We Do About It?" The Journal of Legal Medicine, vol. 39, no. 2, 2019, pp. 137-149.
Hyman DA, Silver C. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It? J Leg Med. 2019;39(2):137-149.
Hyman, D. A., & Silver, C. (2019). Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It? The Journal of Legal Medicine, 39(2), 137-149. https://doi.org/10.1080/01947648.2019.1645542
Hyman DA, Silver C. Why Are We Being Overcharged for Pharmaceuticals? what Should We Do About It. J Leg Med. 2019 Apr-Jun;39(2):137-149. PubMed PMID: 31503533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It? AU - Hyman,David A, AU - Silver,Charles, PY - 2019/9/11/entrez PY - 2019/9/11/pubmed PY - 2020/1/7/medline SP - 137 EP - 149 JF - The Journal of legal medicine JO - J Leg Med VL - 39 IS - 2 SN - 1521-057X UR - https://www.unboundmedicine.com/medline/citation/31503533/Why_are_we_Being_Overcharged_for_Pharmaceuticals_What_Should_We_Do_About_It L2 - http://www.tandfonline.com/doi/full/10.1080/01947648.2019.1645542 DB - PRIME DP - Unbound Medicine ER -